New Agents Committee
The New Agents Committee (NAC) selects new anti-cancer treatments for early clinical trials.
NAC members are expert in early clinical trials of novel agents and other aspects of drug development. Proposals and meetings are confidential. NAC-approved novel agents in development include: molecularly targeted small molecules, cytotoxic agents, antibodies, vaccines, immunotherapy and cell therapy.
Research areas
The NAC is interested in proposals for scientifically-driven trials of novel unregistered anti-cancer agents. NAC reviews:
- Preclinical development prior to a clinical trial
- Phase 1 trials, including first-in-human and first-in-class
- Combination trials of unregistered and registered agents
- Early phase 2 hypothesis-testing trials
How proposals are judged
Proposals are subject to external, international peer review and are judged on the basis of:
- Scientific rationale and importance
- Uniqueness/novelty of the target or agent
- Clinical direction and unmet medical need
- Quality of supporting data in relevant models
Committee chairs and members
Chair of the New Agents Committee
Professor Pat LoRusso – Yale Cancer Center
Vice Chair of the New Agents Committee
Dr Greg Reyes – Independent, San Diego, USA
NAC members
Professor Mark Cragg – University of Southampton
Dr Fieke Froeling - University of Glasgow
Professor Linda Hakes – Independent, Germany
Professor Aslaug Helland - University of Oslo
Dr Sheeba Irshad - Kings College London
Dr Allan Jordan - Sygnature
Mr Bo Kara – Mereo BioPharma
Dr Elaine Kilgour - Redx Pharma
Dr Rebecca Kristeleit - Guy's & St Thomas NHS Foundation Trust
Dr Andy Ryan - Fast Biopharma
Professor Kjetil Tasken – University of Oslo
Professor Fiona Thistlethwaite - University of Manchester
Dr Astrid van der Veldt - Erasmus MC, Rotterdam
Professor Bart Vanhaesebroeck – University College London
Professor Steve Wedge – University of Newcastle
Dr Tim Yap – M D Anderson, University of Texas
Contact for this committee
Schemes reviewed by this committee
Discover more like this
Funds biotherapeutic and small molecule drug discovery.
Oversees funding and endorsement of investigator-led clinical trials